What Might Whistleblower Protections Look Like For UK Pharma Post-Brexit?
In the first of two articles on the whistleblowing landscape, Sean Curran considers how things might change in the UK in the wake of the country's departure from the EU.
You may also be interested in...
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Jakavi joins the likes of Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.